APA (7th ed.) Citation

J, D., J, F., M, N., JE, G., J, S., M, E., . . . M, M. (2025). Comparison of fludarabine/melphalan (FM140) with fludarabine/melphalan/BCNU (FBM110) in patients with relapsed/refractory AML undergoing allogeneic hematopoietic cell transplantation - a registry study on behalf of the EBMT Acute Leukemia Working Party. Bone marrow transplantation, 60(3), 373. https://doi.org/10.1038/s41409-024-02499-6

Chicago Style (17th ed.) Citation

J, Duque-Afonso, et al. "Comparison of Fludarabine/melphalan (FM140) with Fludarabine/melphalan/BCNU (FBM110) in Patients with Relapsed/refractory AML Undergoing Allogeneic Hematopoietic Cell Transplantation - a Registry Study on Behalf of the EBMT Acute Leukemia Working Party." Bone Marrow Transplantation 60, no. 3 (2025): 373. https://doi.org/10.1038/s41409-024-02499-6.

MLA (9th ed.) Citation

J, Duque-Afonso, et al. "Comparison of Fludarabine/melphalan (FM140) with Fludarabine/melphalan/BCNU (FBM110) in Patients with Relapsed/refractory AML Undergoing Allogeneic Hematopoietic Cell Transplantation - a Registry Study on Behalf of the EBMT Acute Leukemia Working Party." Bone Marrow Transplantation, vol. 60, no. 3, 2025, p. 373, https://doi.org/10.1038/s41409-024-02499-6.